Trusted Resource for Clinical Trials, Protocols & Progress
Case Study: Sample Size Re-estimation Sample Size Re-estimation as an Adaptive Mid-Trial Modification Introduction: Why Sample Size May Need Re-estimation Sample size planning is one of the most critical aspects of clinical trial design. However, assumptions about event rates, variance, and treatment effects may prove inaccurate during trial execution. To address this, adaptive designs allow…
What Changes Are Allowed Mid-Trial? Adaptive Modifications Permitted During Clinical Trials Introduction: The Concept of Adaptive Modifications Adaptive trial designs allow pre-specified modifications during the course of a study, based on interim data. The goal is to enhance efficiency, ethical oversight, and scientific validity without compromising trial integrity or inflating Type I error. Regulators such…
Maintaining Power During Interim Looks How to Maintain Statistical Power During Interim Looks in Clinical Trials Introduction: Why Power Matters in Interim Analyses Statistical power—the probability of detecting a true effect—lies at the heart of clinical trial design. When interim analyses are introduced, there is a risk of reducing power due to repeated looks at…
Determining Optimal Sample Sizes in Rare Disease Studies How to Estimate Sample Size in Rare Disease Clinical Trials Introduction: Why Sample Size Planning Is Crucial in Orphan Trials One of the most complex and sensitive decisions in rare disease clinical trials is determining the appropriate sample size. Unlike trials for common diseases where thousands of…
Read More “Determining Optimal Sample Sizes in Rare Disease Studies” »
Implementing Adaptive Designs in Rare Disease Clinical Trials How Adaptive Designs Enhance Rare Disease Clinical Trial Efficiency Why Adaptive Designs Are Ideal for Rare Disease Trials Traditional randomized controlled trials (RCTs) often face feasibility issues in rare disease drug development due to small patient populations, recruitment difficulties, and ethical concerns over placebo use. Adaptive designs—clinical…
Read More “Implementing Adaptive Designs in Rare Disease Clinical Trials” »
Sample Size Re-Estimation in Rare Disease Trials: Adaptive Approaches Optimizing Sample Sizes in Rare Disease Trials through Adaptive Re-Estimation Introduction: The Need for Sample Size Flexibility in Rare Trials Designing adequately powered clinical trials in the context of rare and ultra-rare diseases is inherently difficult due to the limited patient population and variability in disease…
Read More “Sample Size Re-Estimation in Rare Disease Trials: Adaptive Approaches” »
Seamless Phase II/III Trials in Orphan Indications Accelerating Rare Disease Drug Development with Seamless Phase II/III Trial Designs Introduction: Why Seamless Designs Matter in Rare Diseases Traditional clinical trials follow a linear sequence—Phase I to Phase III—often resulting in delays and duplication of efforts. For orphan indications, where patient populations are scarce and unmet needs…
Read More “Seamless Phase II/III Trials in Orphan Indications” »
Why Adaptive Designs Fit Rare Disease Trials The Strategic Role of Adaptive Designs in Rare Disease Clinical Trials Introduction: The Trial Design Challenge in Rare Diseases Rare disease clinical trials are often hindered by challenges like small sample sizes, heterogeneous populations, ethical constraints, and limited natural history data. Traditional randomized controlled trials (RCTs) may not…
Adaptive Designs in Rapid Vaccine Development Using Adaptive Trial Designs to Speed Vaccine Programs—Without Cutting Corners Why Adaptive Designs Fit Rapid Vaccine Development Adaptive designs let vaccine developers learn early and pivot quickly while protecting scientific credibility. In outbreaks or high-burden settings, waiting for fixed, multi-year trials can delay access. With pre-planned rules, sponsors can…
Interim Analysis in Adaptive Trial Settings: A Practical Guide Conducting Interim Analysis in Adaptive Clinical Trials: Best Practices and Strategies Adaptive clinical trials are reshaping drug development by introducing flexibility into trial design without compromising statistical integrity. At the heart of this flexibility lies interim analysis — a planned evaluation of accumulating data that supports…
Read More “Interim Analysis in Adaptive Trial Settings: A Practical Guide” »
